Skip to main content
GenSight Biologics S.A. logo

GenSight Biologics S.A. — Investor Relations & Filings

Ticker · SIGHT ISIN · FR0013183985 LEI · 549300NK4AB8OUEX1F54 PA Manufacturing
Open in API
Filings indexed 628 across all filing types
Latest filing 2025-03-17 Regulatory Filings
Country FR France
Listing PA SIGHT

About GenSight Biologics S.A.

https://www.gensight-biologics.com

GenSight Biologics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative gene therapies for patients with neurodegenerative retinal diseases and disorders of the central nervous system. The company's therapeutic approach is based on two core technology platforms: the Mitochondrial Targeting Sequence (MTS) and optogenetics. Its lead product candidate, LUMEVOQ (lenadogene nolparvovec), is a gene therapy in late-stage clinical development for treating vision loss from rare mitochondrial diseases. The company's pipeline also includes GS030, an optogenetic-based therapy in clinical trials for retinal degenerative diseases.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is a press release ("Communiqué de presse") announcing that GenSight Biologics will present new scientific data and analyses related to its therapy LUMEVOQ® at the 2025 NANOS Annual Congress. It details specific poster presentations and platform sessions, including dates, times, and presenters. This type of announcement, detailing scientific data presentation schedules, is typically classified as an Investor Presentation (IP) or sometimes a Regulatory Filing (RNS) if it were a mandatory disclosure. However, since it is a specific announcement about scientific data being shared at a conference, and it is not a full financial report (10-K, IR) or a general earnings release (ER), it aligns best with the content shared in an Investor Presentation (IP) context, which often includes scientific updates, or potentially a Regulatory Filing (RNS) if it's a required disclosure of scientific progress. Given the focus on scientific updates and KOL presentations, 'Investor Presentation' (IP) is a strong candidate, as these materials often precede or accompany investor briefings. However, since it is purely an announcement of *where* data will be presented, and not the presentation itself, and it is a press release format, it fits the description of a general announcement. Since it is not a financial report, dividend notice, or management change, and it is a specific, non-standard announcement, the fallback category 'Regulatory Filings' (RNS) is often used for press releases detailing scientific milestones or conference participation, unless a more specific category like 'IP' is deemed a better fit for the *content* being announced. Given the options, and the nature of announcing scientific data dissemination, 'IP' (Investor Presentation) captures the essence of the information being highlighted, even if this specific document is the announcement *of* the presentation schedule. If the document were the actual presentation slides, IP would be certain. As a press release detailing scientific updates for investors, IP is the most contextually relevant specific category over the general RNS fallback. I will select IP.
2025-03-17 French
Inside Information / Other news releases
Regulatory Filings Classification · 99% confidence The document is titled 'Press Release' and announces scientific updates regarding the therapy LUMEVOQ® being presented at the NANOS 2025 conference. It details poster and platform presentation schedules, presenters, and locations. This is not a comprehensive financial report (like 10-K or IR), nor is it a formal regulatory filing announcing a major corporate event like a merger or dividend. It is a communication aimed at investors and the scientific community about ongoing research and data presentation. This type of announcement, which details scientific progress and upcoming presentations, most closely aligns with general Investor Relations communication, which often falls under Regulatory Filings (RNS) if no other specific category fits, or potentially Investor Presentation (IP) if it were the presentation itself. Since this is a press release *about* presentations, and not the presentation slides or a formal financial report, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback, although it contains significant investor-facing information. Given the context of scientific data updates, it is a general corporate announcement.
2025-03-17 English
Inside Information / Operations of the issuer (acquisitions, sales...)
Capital/Financing Update Classification · 98% confidence The document is a press release announcing a specific financial transaction: a 'new round of financing' involving the 'issuance of new shares with warrants attached' for a total gross amount of approximately €0.9 million. This directly relates to the company raising capital and changing its capital structure. This fits the definition of 'Capital/Financing Update' (CAP). Although it involves issuing shares (SHA) and affects ownership (MRQ), the primary purpose and focus of the announcement is the financing event itself. It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it details the terms and impact of the capital raise.
2025-03-07 English
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
Share Issue/Capital Change Classification · 99% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces a specific financial transaction: "GenSight Biologics annonce un financement d'un montant d'environ 0,9 million d'euros auprès d'investisseurs existants" (GenSight Biologics announces financing of approximately 0.9 million euros from existing investors). The text details the terms of a capital increase reserved for specialized investors, including the subscription price, the issuance of new shares with warrants (ABSA), and the intended use of proceeds. This clearly falls under the category of updates on company fundraising or capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document is a full announcement, not just a notice of publication.
2025-03-07 French
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 99% confidence The document is titled "GenSight Biologics publie ses résultats financiers consolidés estimés pour l'année 2024" (GenSight Biologics publishes its estimated consolidated financial results for the year 2024). It contains detailed comparative financial tables (Balance Sheet, Income Statement, Cash Flow Statement) for 2023 and 2024, along with extensive management commentary on the financial performance, R&D expenses, and cash position. This content structure is characteristic of a comprehensive annual financial report, even though it is presented as an 'estimated' press release ahead of the final audited filing. Since the document provides the full breakdown of annual financial performance, it aligns best with the Annual Report category (10-K), which covers full yearly performance. Although it is a press release format, the substance is the full annual financial disclosure, not just highlights (ER) or a short factsheet (FS). Given the context of a full-year financial review, 10-K is the most appropriate classification for the underlying report type being disclosed. FY 2024
2025-02-27 French
Inside Information / News release on accounts, results
Earnings Release Classification · 100% confidence The document is explicitly titled 'Press release' and begins with the headline: '# **GenSight Biologics Reports Estimated Full-Year 2024 Consolidated Financial Results**'. It contains summarized financial tables (Balance Sheet and Income Statement components) for the fiscal year 2024 compared to 2023, along with management commentary on the results and outlook. This structure is characteristic of an Earnings Release (ER), which provides the initial announcement of key financial results, often before the full, audited Annual Report (10-K) or the detailed Management Discussion & Analysis (MDA) is finalized or filed. Since it reports 'estimated full-year 2024 consolidated financial results' immediately following the end of the fiscal year, it fits the definition of an Earnings Release (ER) better than the comprehensive 10-K or the detailed MDA. FY 2024
2025-02-27 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.